Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C V...(elivering our technology into India and ...),Health

Date:6/10/2009

elivering our technology into India and other practitioner-driven medical device markets. Pending the outbreak of a pandemic or bioterror threat, our primary focus in these markets will be the treatment of HCV. Such focus is driven by previous Hemopurifier(R) treatment outcomes, the validation that viral filtration increases cure rates, and the magnitude of the HCV treatment opportunity.

Our goal in HCV care is to increase patient cure rates up to 90%. We envision two pathways to reach this goal:

1. Our Hemopurifier(R) as an adjunct treatment to enhance the benefit of SOC therapy; or
2. Our Hemopurifier(R) in combination with a candidate therapy to replace SOC therapy.

The achievement of our goal would significantly impact the HCV treatment industry as SOC therapy succeeds in providing sustained viral responses (SVR) in only 30% to 50% of patients who initiate treatment. HCV infection is considered cured when a SVR of undetectable viral load is maintained more than six months after completing treatment. Prior to discussing the clinical rationale supporting our treatment goals, I want to clarify the magnitude of the HCV treatment opportunity.

It is estimated that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with HCV. To provide perspective, this represents a patient population approximately 5-6 times larger than those infected with HIV/AIDS and over 100 times larger than the population of end stage renal disease (ESRD) patients who require kidney dialysis. However, unlike kidney dialysis and HIV therapeutics, we actually have the opportunity to participate in curing HCV-infected individuals. The global market for therapies to treat HCV is projected to reach $9.1 billion by 2015, and in the United States, the annual cost of advanced liver disease resulting from HCV infect
'/>"/>

SOURCE Aethlon Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
2. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
3. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. MSU engineering team designs innovative medical device
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
8. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
9. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
10. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
11. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions